Cite
HARVARD Citation
Parrondo, R. et al. (2022). Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leukemia & lymphoma. 63 (3), pp. 738-742. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Parrondo, R. et al. (2022). Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leukemia & lymphoma. 63 (3), pp. 738-742. [Online].